Interactions between the cytochrome P450 system and the second-generation antipsychotics.
- 1 March 2003
- journal article
- review article
- Vol. 28 (2), 99-112
Abstract
Awareness of the metabolism of second-generation antipsychotics by the cytochrome P450 (CYP) system can inform the clinician about how to avoid and manage drug-drug interactions involving these enzymes. Clozapine is metabolized primarily by CYP1A2, with additional contributions by CYP2C19, CYP2D6 and CYP3A4. Risperidone is metabolized primarily by CYP2D6 and to a lesser extent by CYP3A4. Olanzapine is metabolized primarily by CYP1A2 and to a lesser extent by CYP2D6. Quetiapine and ziprasidone are metabolized by CYP3A4. At the usual clinical doses, these drugs appear not to significantly affect the metabolism of other medications. There is, however, a lack of in vivo metabolic data, especially for the 3 newest second-generation antipsychotics: olanzapine, quetiapine and ziprasidone.Keywords
This publication has 100 references indexed in Scilit:
- Biotransformation of Post-Clozapine AntipsychoticsClinical Pharmacokinetics, 2000
- QuetiapineDrug Safety, 2000
- OlanzapineClinical Pharmacokinetics, 1999
- Inhibition and Induction of Cytochrome P450 and the Clinical ImplicationsClinical Pharmacokinetics, 1998
- The involvement of CYP1A2 and CYP3A4 in the metabolism of clozapineBritish Journal of Clinical Pharmacology, 1997
- Use of In Vitro and In Vivo Data to Estimate the Likelihood of Metabolic Pharmacokinetic InteractionsClinical Pharmacokinetics, 1997
- P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclaturePharmacogenetics, 1996
- The influence of rifampin treatment on caffeine clearance in healthy manJournal of Hepatology, 1995
- Extrahepatic Metabolism of Drugs in HumansClinical Pharmacokinetics, 1994
- P450 EnzymesClinical Pharmacokinetics, 1992